Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B

키워드

참고문헌 (40)

1. Liaw YF, "Hepatitis B virus infection", Lancet, 373, pp.582~592 (2009)
2. Perz JF, "The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide", J Hepatol, 45, pp.529~538 (2006)
3. Yuen MF, "Treatment of chronic hepatitis B: evolution over two decades", J Gastroenterol Hepatol, 26(1), pp.138~143 (2011)
4. Chan HL, "Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial", Ann Intern Med, 147, pp.745~754 (2007)
5. Liaw YF, "2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B", Gastroenterology, 136, pp.486~495 (2009)
6. Hadziyannis SJ, "Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years", Gastroenterology, 131, pp.1743~1751 (2006)
7. Mauss S, "Antiretroviral therapy with tenofovir is associated with mild renal dysfunction", AIDS, 19, pp.93~95 (2005)
8. Gane EJ, "Telbivudine improves renal function in patients with chronic hepatitis B", Gastroenterology, 146, pp.138~146 (2014)
9. Levey AS, "A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group", Ann Intern Med, 130, pp.461~470 (1999)
10. Cuddy ML, "Treatment of hypertension: guidelines from JNC 7 (the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 1)", J Pract Nurs, 55, pp.17~21 (2005)
11. American Diabetes Association, "Standards of medical care in diabetes: 2011", Diabetes Care, 34(1), pp.S11~S61 (2011)
12. Zou XJ, "Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine", J Viral Hepat, 18, pp.892~896 (2011)
13. Kim BK, "Clevudine myopathy in patients with chronic hepatitis B", J Hepatol, 51, pp.829~834 (2009)
14. Ha NB, "Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil", Hepatology, 50, pp.727~734 (2009)
15. Lange CM, "Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function", Hepatology, 50, pp.2001~2006 (2009)
16. Schiefke I, "Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection", World J Gastroenterol, 11, pp.1843~1847 (2005)
17. Izzedine H, "Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies", Kidney Int, 66, pp.1153~1158 (2004)
18. Gish RG, "Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B", Clin Gastroenterol Hepatol, 10, pp.941~946 (2012)
19. Iloeje UH, "Predicting cirrhosis risk based on the level of circulating hepatitis B viral load", Gastroenterology, 130, pp.678~686 (2006)
20. Chang TT, "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B", N Engl J Med, 354, pp.1001~1010 (2006)
21. 권대훈, "Continuous Long-Term Entecavir Therapy in Naïve Chronic Hepatitis B Patients Showing Partial Virologic Response", Gut and Liver, 7(6), pp.712~718 (2013), 거트앤리버 발행위원회
22. Kim MN, "Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir", Liver Int, 34, pp.1216~1223 (2014)
23. Kim MN, "Risk assessment of liver-related events using transient elastography in patients with chronic hepatitis B receiving entecavir", J Clin Gastroenterol, 48, pp.272~278 (2014)
24. Chang TT, "Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B", Hepatology, 51, pp.422~430 (2010)
25. Gish RG, "Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B", Gastroenterology, 133, pp.1437~1444 (2007)
26. Lai CL, "Telbivudine versus lamivudine in patients with chronic hepatitis B", N Engl J Med, 357, pp.2576~2588 (2007)
27. Zeuzem S, "Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B", J Hepatol, 51, pp.11~20 (2009)
28. Park H, "Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir", World J Gastroenterol, 19, pp.7671~7679 (2013)
29. Ahn SH, "Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B", Hepatol Int, 6, pp.696~706 (2012)
30. Chan HL, "Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis", J Viral Hepat, 19, pp.732~743 (2012)
31. Tsai MC, "A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice", J Antimicrob Chemother, 67, pp.696~699 (2012)
32. Nishimura M, "Significance of estimating the glomerular filtration rate for the management of hypertension in type 2 diabetes with microalbuminuria", Hypertens Res, 36, pp.705~710 (2013)
33. American Diabetes Association, "Standards of medical care in diabetes: 2014", Diabetes Care, 37(1), pp.S14~S80 (2014)
34. Whaley-Connell AT, "CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004", Am J Kidney Dis, 51, pp.S13~S20 (2008)
35. Buckalew VM Jr, "Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. Modification of Diet in Renal Disease Study Group", Am J Kidney Dis, 28, pp.811~821 (1996)
36. du Cheyron D, "The attributable mortality of acute renal failure in critically ill patients with liver cirrhosis", Intensive Care Med, 31, pp.1693~1699 (2005)
37. Garcia-Tsao G, "Acute kidney injury in cirrhosis", Hepatology, 48, pp.2064~2077 (2008)
38. D’Amico G, "Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies", J Hepatol, 44, pp.217~231 (2006)
39. Al Sibae MR, "Accuracy of MELD scores in predicting mortality in decompensated cirrhosis from variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, or acute liver failure as well as mortality after non-transplant surgery or TIPS", Dig Dis Sci, 56, pp.977~987 (2011)
40. Liang KH, "Decrease of serum angiotensin converting enzyme levels upon telbivudine treatment for chronic hepatitis B virus infection and negative correlations between the enzyme levels and estimated glumerular filtration rates", Hepat Mon, 14, pp.e15074~ (2014)

관련 논문AI추천